Home » Spinal muscular atrophy (Sma), green light from Aifa to extend reimbursement for SMA gene therapy

Spinal muscular atrophy (Sma), green light from Aifa to extend reimbursement for SMA gene therapy

by admin
Spinal muscular atrophy (Sma), green light from Aifa to extend reimbursement for SMA gene therapy

by Health Editorial Staff

The Italian Medicines Agency has approved the extension of reimbursement for the first gene therapy for SMA, which opens up further treatment prospects for the community of young patients affected by the rare neuromuscular disease

Spinal muscular atrophy (Sma) is a rare and serious neuromuscular pathology, as well as the leading cause of genetic childhood death, characterized by the progressive loss of motor skills, which occurs when the version of a gene necessary to produce a essential protein known as “survival motor neuron” protein (Smn).

On the treatment front, the Italian Medicines Agency (AIFA) has recently given the green light to the extension of the reimbursement of onasemnogene abeparvovec, the first gene therapy for SMA, to children with SMA 2 up to 13.5kg and to pre- symptomatic with 3 copies of the Smn2 gene, thus opening up further treatment prospects for the community of young patients with spinal muscular atrophy and their families.

The situation in Italy

In Italy approximately 40-50 children are born with spinal muscular atrophy every year; precisely the lack of Smn protein, which causes the death of the nerves that control the muscles (motoneurons), makes daily gestures such as sitting and standing, and in the most serious cases swallowing and breathing difficult. SMA is a “disease continuum”, with a range of symptoms that can vary in severity, so much so that different types of SMA can be classified. Among these, SMA type 1, whose symptoms develop at the age of 6 months, and SMA type 2, with symptoms appearing between 6 and 18 months of age, are the most serious.

See also  MotoGP 2023. Spanish GP. Jerez report cards: Praise for Bagnaia, applause for Binder, Miller and Pedrosa - MotoGP

Extended refundability

From today, with the extension of the reimbursement indications, the first gene therapy approved in Italy, onasemnogene abeparvovec, is also available for patients suffering from spinal muscular atrophy type 2 (Sma2) and for pre-symptomatic patients with 3 copies of Smn2 and up to 13.5 kg. Thus expanding the audience of young patients who will be able to access this treatment, at a time when neonatal screening, fundamental for the timely diagnosis of the pathology, is extending to more and more Italian regions.

The importance of newborn screening

«We welcome the news of the expansion of access to gene therapy which will be made available – declares in this regard Anita Pallara, president of the FamiglieSMA Association – for a greater number of children affected by spinal muscular atrophy. We know that gene therapy increases its effectiveness and, therefore, improves the patient’s response the earlier it is administered. For this reason, as the FamiglieSMA Association we reiterate the importance of neonatal screening, which must be extended to all regions in order to guarantee the same right to health throughout the national territory. Alongside screening, we also underline the importance of guaranteeing families the necessary accompaniment in the treatment process and in the subsequent post-treatment follow-up phases, through care by specialized centers across the entire national territory.”

I study

Supporting the reimbursement extension was the completion of the phase III SPR1NT study, which demonstrated how small patients with three copies of the Smn2 backup gene, treated pre-symptomatically, achieved motor goals appropriate for their age , including the ability to stand and walk.

The same study also confirms the importance of neonatal screening for SMA, which significantly increases the probability of identifying patients affected by the disease when they are pre-symptomatic, with a significant impact on potential therapeutic outcomes. Making it possible to administer the therapy, in the first days of life, to 95% of children who would have developed, due to the genetic mutation, the most serious forms of the pathology (Sma1 – Sma2 phenotypes).

See also  Labels on wine, beer and spirits as on cigarettes: EU green light for Irish law. Coldiretti: "An attack on Italy"

Motor development almost similar to that of healthy peers

«The early administration of this innovative treatment allows for better results to be achieved in halting the progression of the disease: prenatal diagnosis, by increasing the probability of identifying patients affected by the disease when they are pre-symptomatic, plays an important role in contributing to potential therapeutic outcomes – specifies Marika Pane, clinical director of the Nemo Pediatric Center in Rome and Associate Professor of Child Neuropsychiatry at the Catholic University of the Sacred Heart in Rome -. It is therefore necessary to take into account the fact that the degeneration of motor neurons begins before birth, intensifies rapidly and that the process cannot be reversed. The innovative aspect of this treatment is that it intervenes directly on the genetic defect with a single administration; therefore, it is carried out only once in a lifetime. Based on the available clinical studies, early treatment allows young patients to achieve motor development stages that are similar to those of healthy peers, such as head control and the ability to sit without support, without the need to resort to supports. ventilators that the history of the disease normally requires.”

In Italy, treatment has already been administered to 125 children

Onasemnogene abeparvovec had already obtained reimbursement approval in Italy in March 2021 as the first single-administration gene therapy for spinal muscular atrophy type 1 (Sma1) designed to directly address the genetic cause of the disease, replacing the function of the missing or non-functioning Smn1 gene in order to halt disease progression with a single intravenous administration.

See also  German Bundestag - Health Committee re-engages with ME/CFS

Precisely with the advent of gene therapy, the community of SMA patients and their families has seen the natural history of the disease change. As demonstrated by the data on the use of onasemnogene abeparvovec in normal clinical practice in Italy (Real World Evidence, RWE), confirming that what is reported by international clinical studies translates into effective benefits for patients treated in our country , where around 125 children have already been involved.

April 23, 2024 (modified April 23, 2024 | 2:49 pm)


You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy